Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The urokinase-type plasminogen activator receptor (uPAR) is overexpressed in several cancers including glioblastoma (GBM) and is an established biomarker for metastatic potential.
|
28316028 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
|
21896743 |
2011 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, these results suggest that c-Src, mitogen-activated protein kinase, and a composite activator protein 1 on the uPA promoter are responsible for EGF-induced uPA expression and GBM invasion.
|
20467333 |
2010 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastoma multiforme (GM), the most frequent primary malignant brain tumor, is highly invasive due to the expression of proteases, including urokinase-type plasminogen activator (uPA).
|
20606645 |
2010 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
|
18819934 |
2008 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion.
|
18355442 |
2008 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A correlation between overexpression of urokinase-type plasminogen activator receptor (uPAR) and glioblastoma invasion has also been established.
|
17273768 |
2007 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In xenograft glioblastoma mouse model and in vitro transmembrane invasion assay, LRP-deficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded extensively the surrounding normal brain tissue, whereas the LRP-overexpressing and uPA-deficient cells did not invade into the surrounding normal brain. siRNA, targeted against uPA in LRP-deficient clones, attenuated their invasive potential.
|
17974965 |
2007 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A bispecific immunotoxin (IT) called DTAT13 was synthesized in order to target simultaneously the urokinase-type plasminogen activator receptor (uPAR)-expressing tumor neovasculature and IL-13 receptor expressing glioblastoma cells with the goal of intratumoral administration for brain tumors.
|
15047912 |
2004 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stably transfecting human glioblastoma cells with antisense uPA decreased the amount of cell-bound uPA and disrupted actin cytoskeleton formation and cell migration.
|
12545160 |
2003 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells.
|
12420219 |
2002 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reported previously that the production of urokinase-type plasminogen activator receptor (uPAR) protein is greater in high-grade glioblastomas than in low-grade gliomas.
|
11234878 |
2001 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the role of uPA in the invasive process of brain tumors, we stably transfected a human glioblastoma cell line SNB19 with a vector capable of expressing an antisense transcript complementary to the 1020 bases at the 3' end of the uPA cDNA.
|
11489835 |
2001 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We further studied the activation and inhibition of uPA promoter by co-expression of a transactivation domain lacking c-jun: a dominant negative ERK1 and ERK2 mutant and a dominant negative c-raf in glioblastoma cell line showed repressed uPA promoter activity compared with the effect of the empty expression vector.
|
11115541 |
2001 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of uPA mRNA expression in tumor tissues with recurrence during 18 postoperative months and a survival period less than 3 years, were significantly higher than counterparts (P < 0.01). uPA mRNA expression was strongly correlated with the microvessel quantity (MVQ) in gliomas (r = 0.56, P < 0.01). uPA protein was mainly distributed in tumor cells and endothelial cells of glioblastomas and anaplastic astrocytomas.
|
11776074 |
2000 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells.
|
11688967 |
2000 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The distribution of uPA protein in the immunoreactivity was mainly in tumor cells and microvascular endothelial cells of glioblastomas and anaplastic astrocytomas, localizing at cytoplasms, especially near sites of vascular proliferation and at the leading edges of tumors.
|
10914816 |
2000 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The distribution of uPA protein immunoreactivity was mainly in tumour cells and microvascular endothelial cells of glioblastomas and anaplastic astrocytomas, localising in the cytoplasm, especially at sites of vascular proliferation and at the leading edges of tumours.
|
10844794 |
2000 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glioblastomas express more urokinase-type plasminogen activator receptor (uPAR) than do low-grade gliomas and normal brain tissue.
|
10853019 |
2000 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus uPAR appears in this model to be essential for tumorigenicity and invasion of glioblastomas in vivo.
|
9219733 |
1997 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, adherent human U-251MG glioblastoma cells in vitro expressed u-PAR and u-PA proteins, which localized to sites of integrin alpha nu beta 3 cell-matrix contacts.
|
7747809 |
1995 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunocytochemical staining for uPA showed strong immunoreactivity in the tumor cells and vasculature of glioblastomas and anaplastic astrocytomas but undetectable or very low immunoreactivity for uPA in low-grade gliomas and normal brain tissues. uPA mRNA was located in astrocytoma and endothelial cells and was heterogeneously distributed within glioblastoma, with preferential localization near vascular proliferation and at the leading edge of the tumor. uPA expression was dramatically higher in highly malignant astrocytomas, especially glioblastomas, and was correlated with malignant progression of astrocytomas.
|
8033079 |
1994 |